Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cerus CE marks Intercept for frozen plasma

This article was originally published in Clinica

Executive Summary

Concord, California company Cerus has CE marked its Intercept blood system, allowing its sale in Europe to purify previously frozen plasma. Intercept is designed to reduce the risk of diseases being transmitted in contaminated blood by inactivating a broad range of viral, bacterial and parasitic pathogens, as well as harmful white blood cells that may be present in donated blood. The expanded claim means that blood banks in countries that recognise the CE mark may now use Intercept to purify either previously frozen or freshly collected plasma. This will help to permit the use of imported plasma and plasma in quarantined inventory, both of which are previously frozen. Cerus CE marked the Intercept system for platelets in 2002 and for fresh plasma in 2006 (see Clinica No 1236, p 22).

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT043514

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel